| 包装 | 库存 | 价格 | |
|---|---|---|---|
暂无数据 | |||
推荐产品
基本信息
英文别名(5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol | |
中文别名(5Z,7E,22E)-9,10-开环麦角甾-5,7,10,22-四烯-1,3-二醇 | |
MDL编码MFCD01076571 |
安全信息
存储条件Freezer -20℃ | Symbol |
Signal WordDanger | Hazard StatementsH300 |
Precautionary StatementsP264 P270 P321 P330 P405 P501 P301+P316 | |
UN2811 | Hazard Class6.1 |
Packing GroupI | RTECSVS2950000 |
化学和物理性质
MP140 |
产品描述
生化/生理作用
Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA). Doxercalciferol acts as a pro-hormone, needing 25-hydroxylation in the liver for bioactivation into 1α, 25-hydroxyvitamin D2. Pivotal studies in adults on dialysis have demonstrated control of secondary hyperparathyroidism that is superior to placebo therapy, without undue suppression of 1st IMA-PTH < 300 pg/mL, or occurrences of hypercalcemia. Doxercalciferol has been shown to be effective in controlling secondary hyperparathyroidism of adult patients with CKD stages 3-4.Doxercalciferol is a vitamin D2 analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D2. Despite its relatively low affinity for the vitamin D receptor (VDR) (before activation), it is effective at suppressing expression of the parathyroid hormone (PTH) gene, and appears to act through the VDR.